Management of afatinib-induced stomatitis

Kato,Saeko; Saito,Anna; Matsuda,Naomi; Suzuki,Hisako; Ujiie,Midori; Sato,Shinya; Miyazaki,Kunihiko; Kodama,Takahide; Satoh,Hiroaki

doi:10.3892/mco.2017.1184

Management of afatinib-induced stomatitis

Authors:
- Saeko Kato
- Anna Saito
- Naomi Matsuda
- Hisako Suzuki
- Midori Ujiie
- Shinya Sato
- Kunihiko Miyazaki
- Takahide Kodama
- Hiroaki Satoh
View Affiliations

Affiliations: Division of Nursing, Ryugasaki Saiseikai Hospital, Ryugasaki, Ibaraki 301-0854, Japan, Division of Respiratory Medicine, Ryugasaki Saiseikai Hospital, Ryugasaki, Ibaraki 301-0854, Japan, Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 310-0015, Japan
Published online on: March 8, 2017 https://doi.org/10.3892/mco.2017.1184
Pages: 603-605

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Severe stomatitis may lead to the need to interrupt or discontinue cancer therapy and, thus, may affect control of the primary disease. Stomatitis may also increase the risk of local and systemic infection and significantly affects the quality of life and the cost of care. The present study was conducted to evaluate the efficacy of two traditional herbal medicines in controlling treatment-induced stomatitis in a small cohort of lung cancer patients treated with afatinib. All patients who were treated with afatinib for epidermal growth factor receptor (EGFR) mutated nonsmallcell lung cancer (NSCLC) between January, 2015 and March, 2016, were included in this study. During the study period, a total of 14 NSCLC patients were treated with afatinib, an EGFR-tyrosine kinase inhibitor (TKI). Two patients already had stomatitis at the time of initiation of afatinib therapy; among the remaining 12 NSCLC patients, 2 (16.7%) developed stomatitis. All the lesions in the 4 patients who developed stomatitis were completely alleviated after 2 weeks of therapy with Aznol mouthwash, a chamomile extract with anti-inflammatory effects, and Hangeshashinto, a traditional herbal (Kampo) medicine. Afatinib therapy was re-initiated, but none of the patients developed stomatitis thereafter. To the best of our knowledge, this is the first report evaluating oral care and management of stomatitis. This type of care and treatment may reduce the incidence of complications associated with EGFR-TKI therapy.

View Figures

View References

1	Califano R, Tariq N, Compton S, Fitzgerald DA, Harwood CA, Lal R, Lester J, McPhelim J, Mulatero C, Subramanian S, et al: Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK. Drugs. 75:1335–1348. 2015. View Article : Google Scholar : PubMed/NCBI
2	Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, et al: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 31:3327–3334. 2013. View Article : Google Scholar : PubMed/NCBI
3	Ge ZD, Auchampach JA, Piper GM and Gross GJ: Comparison of cardioprotective efficacy of two thromboxane A2 receptor antagonists. J Cardiovasc Pharmacol. 41:481–488. 2003. View Article : Google Scholar : PubMed/NCBI
4	Rekka E, Chrysselis M, Siskou I and Kourounakis A: Synthesis of new azulene derivatives and study of their effect on lipid peroxidation and lipoxygenase activity. Chem Pharm Bull. 50:904–907. 2002. View Article : Google Scholar : PubMed/NCBI
5	Akagi M, Matsui N, Mochizuki S and Tasaka K: Inhibitory effect of egualen sodium: A new stable derivative of azulene on histamine release from mast cell-like cells in the stomach. Pharmacology. 63:203–209. 2001. View Article : Google Scholar : PubMed/NCBI
6	Kourounakis AP, Rekka EA and Kourounakis PN: Antioxidant activity of guaiazulene and protection against paracetamol hepatotoxicity in rats. J Pharm Pharmacol. 49:938–942. 1997. View Article : Google Scholar : PubMed/NCBI
7	Yano S, Horie S, Wakabayashi S, Mochizuki S, Tomiyama A and Watanabe K: Increasing effect of sodium 3-ethyl-7-isopropyl-1-azulenesulfonate 1/3 hydrate (KT1-32), a novel antiulcer agent, on gastric mucosal blood flow in anesthetized. Res Commun Chem Pathol Pharmacol. 70:253–256. 1990.PubMed/NCBI
8	Okabe S, Takeuchi K, Mori Y, Furukawa O and Yamada Y: [Effects of KT1-32 on acute gastric lesions and duodenal ulcers induced in rats]. Nippon Yakurigaku Zasshi. 88:467–476. 1986.(in Japanese). View Article : Google Scholar : PubMed/NCBI
9	Seki J, Mukai H and Sugiyama M: Studies on the absorption of sodium guaiazulene-3-sulfonate. II. Absorption mechanism from nasal and intestinal membrane. J Pharmacobiodyn. 8:337–343. 1985. View Article : Google Scholar : PubMed/NCBI
10	Hanzlik RP and Bhatia P: Metabolism of azulene in rats. Xenobiotica. 11:779–783. 1981. View Article : Google Scholar : PubMed/NCBI
11	Matsuda C, Munemoto Y, Mishima H, Nagata N, Oshiro M, Kataoka M, Sakamoto J, Aoyama T, Morita S and Kono T: Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis. Cancer Chemother Pharmacol. 76:97–103. 2015. View Article : Google Scholar : PubMed/NCBI
12	Yamashita T, Araki K, Tomifuji M, Kamide D, Tanaka Y and Shiotani A: A traditional Japanese medicine-Hangeshashinto (TJ-14)-alleviates chemoradiation-induced mucositis and improves rates of treatment completion. Support Care Cancer. 23:29–35. 2015. View Article : Google Scholar : PubMed/NCBI
13	Aoyama T, Nishikawa K, Takiguchi N, Tanabe K, Imano M, Fukushima R, Sakamoto J, Oba MS, Morita S, Kono T, et al: Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis. Cancer Chemother Pharmacol. 73:1047–1054. 2014. View Article : Google Scholar : PubMed/NCBI
14	Kono T, Kaneko A, Matsumoto C, Miyagi C, Ohbuchi K, Mizuhara Y, Miyano K and Uezono Y: Multitargeted effects of hangeshashinto for treatment of chemotherapy-induced oral mucositis on inducible prostaglandin E2 production in human oral keratinocytes. Integr Cancer Ther. 13:435–445. 2014. View Article : Google Scholar : PubMed/NCBI
15	Okumi H and Koyama A: Kampo medicine for palliative care in Japan. Biopsychosoc Med Jan. 8:62014. View Article : Google Scholar
16	Ohnishi S and Takeda H: Herbal medicines for the treatment of cancer chemotherapy-induced side effects. Front Pharmacol. Feb;10(6): 142015.https://doi.org/10.3389/fphar.2015.00014
17	Naidu MU, Ramana GV, Rani PU, Mohan IK, Suman A and Roy P: Chemotherapy-induced and/or radiation therapy-induced oral mucositis-complicating the treatment of cancer. Neoplasia. 6:423–431. 2004. View Article : Google Scholar : PubMed/NCBI
18	Ke EE and Wu YL: Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: A review of the clinical evidence. Ther Adv Respir Dis. 10:256–264. 2016. View Article : Google Scholar : PubMed/NCBI
19	Bardy J, Molassiotis A, Ryder WD, Mais K, Sykes A, Yap B, Lee L, Kaczmarski E and Slevin N: A double-blind, placebo-controlled, randomised trial of active manuka honey and standard oral care for radiation-induced oral mucositis. Br J Oral Maxillofac Surg. 50:221–226. 2012. View Article : Google Scholar : PubMed/NCBI
20	Ogata J, Minami K, Horishita T, Shiraishi M, Okamoto T, Terada T and Sata T: Gargling with sodium azulene sulfonate reduces the postoperative sore throat after intubation of the trachea. Anesth Analg. 101:290–293. 2005. View Article : Google Scholar : PubMed/NCBI
21	Yen SH, Wang LW, Lin YH, Jen YM and Chung YL: Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys. 82:1463–1470. 2012. View Article : Google Scholar : PubMed/NCBI